How should the dose in milligrams be increased when intestinal absorption is impaired?

Dose Adjustment Strategy for Impaired Intestinal Absorption

When intestinal absorption is impaired, avoid simply increasing oral doses—instead, switch to alternative routes (parenteral, transdermal, suppositories) or change formulations (liquids, crushed tablets) while monitoring therapeutic efficacy and plasma drug levels. 1

Primary Approach: Route and Formulation Changes Over Dose Escalation

The 2021 ESPEN guidelines explicitly recommend that when oral absorption is compromised, the solution is not routinely to increase the milligram dose but rather to change the delivery method 1. This approach prioritizes:

• Parenteral administration (IV, subcutaneous)
• Transdermal delivery when available
• Rectal suppositories for appropriate medications
• Liquid formulations instead of tablets/capsules
• Crushed tablets or opened capsules when appropriate

When Dose Adjustment May Be Considered

If maintaining oral administration is necessary, dose adjustments should be:

Guided by Objective Monitoring

• Measure plasma drug concentrations when available 1
• Monitor therapeutic endpoints (e.g., blood pressure for antihypertensives, INR for warfarin)
• Titrate based on clinical response, not arbitrary increases 1

Individualized Based on Three Key Factors

1. Gastrointestinal anatomy - Remaining bowel length and which segments are intact
2. Absorptive capacity of remnant bowel - Varies dramatically between patients
3. Drug physicochemical characteristics - Absorption site, solubility, dissolution requirements 1

Formulation-Specific Strategies

Avoid These Formulations Entirely

• Sustained-release preparations - Require prolonged intestinal contact time 2
• Delayed-release formulations - May pass through before releasing drug 2
• Enteric-coated tablets - Depend on specific pH and transit time

Prefer These Alternatives

• Liquid formulations - Demonstrated superior absorption even with impaired conditions 3
• Immediate-release tablets that can be crushed
• Solutions or suspensions - Bypass dissolution step 2

Common Pitfalls to Avoid

Do not blindly escalate oral doses without considering that:

• Drugs absorbed primarily in bypassed segments will remain poorly absorbed regardless of dose 4, 5
• High doses of poorly absorbed drugs may cause local GI toxicity without systemic benefit
• Some medications (NSAIDs, bisphosphonates) pose increased risk in altered GI anatomy 4

Do not assume all drugs behave similarly - absorption sites vary:

• Most drugs absorb in proximal jejunum and can work if this segment remains 2
• Drugs requiring specific intestinal segments will fail if those areas are absent 4, 5

Practical Algorithm

1. Assess if therapeutic effect is adequate with current regimen
2. If inadequate response:
   • First: Check plasma levels if available
   • Second: Consider alternative route (parenteral/transdermal/rectal) 1
   • Third: If oral route necessary, switch to liquid formulation 3
   • Fourth: Only then consider dose escalation with close monitoring 1
3. Monitor objective endpoints - never dose blindly 1

Supporting Evidence for Liquid Formulations

Research demonstrates that liquid formulations maintain absorption even when tablet absorption fails. For example, levothyroxine liquid corrected malabsorption in patients where tablets failed due to altered gastric pH 3. This principle applies broadly to impaired absorption states.

The 2022 AGA guidelines reinforce that alternative drug delivery methods should be considered before dose escalation in short bowel syndrome and other malabsorptive conditions 2.